Androgenic alopecia
Conditions
Interventions
Experimental Group (Phase One):The dose escalation test was divided into three dose groups, A, B, and C, with three subjects in each group. In Group A, there was one injection point for every 1cm^2 ar
Experimental Group (Phase Two):Umbilical cord mesenchymal stem cell exosome therapy
Control Group (Phase Two):Minoxidil treatment
Sponsors
Shenzhen People's Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: 1.Male patients aged 18-35; 2.Clinically diagnosed with androgenic alopecia, Hamilton Norwood Scale III-V, moderate degree of alopecia; 3.Patients who voluntarily participate in clinical trials and sign informed consent forms;
Exclusion criteria
Exclusion criteria: 1.Known alcohol allergy; 2.Patients with severe primary diseases of cardiovascular, cerebrovascular, liver, kidney endocrine or hematopoietic system; 3.Patients with other scalp diseases or hair loss diseases; 4.Patients with severe mental illness and cognitive impairment; 5.Patients with poor nutritional status and low immune function; 6.Within 1 year, the system has used corticosteroids, immunosuppressants, cytotoxic drugs and peripheral vasodilators Material person; 7.Within 6 months, those who have used systemic or local drugs to treat hair loss, such as finasteride, minoxidil, etc; 8.Within 3 months, those who have received other clinical trial drugs; 9.Family genetic history or other criteria considered unsuitable by researchers;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair density;Hair diameter;Hair count; | — |
Countries
China
Contacts
Public ContactJianglin Zhang
Shenzhen People's Hospital
Outcome results
None listed